Table 2.
Bivariate and multivariate logistic regression of risk factors for colistin methanesulfonate-associated nephrotoxicity
| Entire cohort (n = 67) | Nephrotoxicity group (n = 51) | No nephrotoxicity group (n = 16) | Bivariate analysis | Multivariate logistic regression | ||
|---|---|---|---|---|---|---|
| P value | OR (95% CI) | P value | ||||
| Age (years)a | 57.48 (±24.01) | 61.53 (±22.44) | 44.56 (±24.99) | 0.013 | 0.98 (0.96–1.04) | 0.494 |
| Body weight (kg)a | 73.67 (±21.33) | 72.78 (±18.90) | 76.50 (±28.26) | 0.547 | - | - |
| Male genderb | 45 (67.2%) | 33(76.1%) | 12 (75.0%) | 0.55 | - | - |
| Charlson Co-morbidity Scorea | 2.88 (±2.39) | 2.86 (±2.14) | 2.94 (±3.15) | 0.914 | - | - |
| Diabetes mellitusb | 29 (43.2%) | 25 (49.0%) | 4 (25.0%) | 0.15 | 0.52 (0.06–4.87) | 0.568 |
| Baseline CrCl (mL/min)a | 133.60 (±92.54) | 126.02 (±85.57) | 157.94 (±111.52) | 0.23 | 0.99 (0.98–4.87) | 0.108 |
| Baseline serum albumin (mg/L)a | 28.65 (±4.45) | 27.86 (±4.19) | 31.19 (±4.48) | 0.008 | 0.72 (0.57–0.93) | 0.010 |
| Intensive care unit careb | 21 (31.3%) | 13 (25.5%) | 8 (50.0%) | 0.12 | 16.38 (1.37–195.55) | 0.027 |
| Receipt of CMS Loading dose | 52 (77.6%) | 39 (76.5%) | 13 (81.3%) | 1.0 | - | - |
| CMS Dose (mU/kg/day)a | 0.11 (±0.04) | 0.11 (±0.04) | 0.10 (±0.04) | 0.48 | - | - |
| Cumulative CMS dose (mU)a | 101.21 (±47.37) | 106.47 (±45.91 | 84.44 (±49.56) | 0.105 | 1.00 (1.00–1.00) | 0.133 |
| Duration of CMS therapy (days)a | 13.76 (±6.77) | 14.16 (±5.54) | 12.50 (±9.86) | 0.397 | 0.96 (0.83–1.11) | 0.555 |
| Number of concomitant nephrotoxic agentsa | 0.71 (±0.62) | 0.76 (±0.65) | 0.56 (±0.51) | 0.26 | 2.37 (0.50–11.19) | 0.277 |
| Concomitant vancomycin therapyb | 33 (49.3%) | 24 (47.1%) | 9 (56.3%) | 0.576 | - | - |
| Concomitant furosemide therapyb | 11 (16.4%) | 8 (15.7%) | 3 (18.75%) | 0.715 | - | - |
| Concomitant aminoglycoside therapyb | 3 (4.47%) | 2 (3.92%) | 1 (6.25%) | 0.559 | - | - |
| Concomitant NSAIDb | 2 (2.98%) | 2 (3.92%) | 0 (0.0%) | 1.00 | - | - |
| Concomitant radiological contrastb | 1 (1.49%) | 1 (1.96%) | 0 (0.0%) | 1.00 | - | - |
| Concomitant amphotericin b therapyb | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.00 | - | - |
CrCl = creatinine clearance; CMS = colistin methanesulfonate; OR = odds ratio; NSAID = Non-steroidal anti-inflammatory drugs.
aMean (± standard deviation).
bNumber (percentage).